3BNC117 vs Lotivibart

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HIV

Shared mechanism: HIV envelope · full HIV pipeline

3BNC117

Developed by Frontier Biotechnologies and partners

Phase 2 in HIVmonoclonal antibody
Partial signal

NCT03041012 · Phase 2 · completed

This open-label, randomized Phase 1b/2a trial assigned 55 people newly diagnosed with HIV-1 to four groups: standard antiretroviral therapy alone, or with the antibody 3BNC117, romidepsin, or both. The first primary measure, the early fall in blood virus levels, was faster with 3BNC117 plus romidepsin than with therapy alone between days 10 and 24 (P=0.048). The second primary measure, the number of immune cells that carry intact virus after one year, fell in all groups, with no significant difference between groups. Because one primary measure was met and one was missed, the result is mixed. The figures come from the peer-reviewed report of the trial in Nature Medicine.

Reported efficacy

Plasma HIV RNA kinetics (3 months); Quantification of the size of the proviral HIV reservoir (1 year); Time to viral rebound during ATI (12 weeks): Co-primary 1, plasma HIV-1 RNA decay rate, ART+romidepsin+3BNC117 vs ART only: daily decay 16.9% (95% CI -27.3% to -4.93%) vs 10.0% (95% CI -14.9% to -4.86%) from day 10 to 24 (P=0.048); comparable from day 0 to 10 and day 24 to 90, met. Co-primary 2, change in intact HIV-1 provirus frequency from baseline to day 365: all groups decreased, with no significant differences between the groups, missed. (mixed)

Result source: NCT03041012

Lotivibart

Developed by ViiV Healthcare

Phase 2 in HIVmonoclonal antibody
Weak signal

NCT04871113 · Phase 2 · completed

Participants were randomized among dose cohorts, but the study was open-label, had no placebo or active comparator during monotherapy, and included only 6 to 16 participants per cohort. The primary endpoint was the surrogate measure of maximum decline in HIV-1 RNA and was reported descriptively without a formal comparative efficacy test, so the findings do not establish comparative treatment benefit.

Next expected readout: January 2027 · NCT07053384 (registry estimate)

Reported efficacy

Maximum Decline From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) Levels - Monotherapy Phase (Baseline (Day 1) and up to Day 84 or end of Monotherapy Phase); Number of Participants With Adverse Events (AEs) - Monotherapy Phase (Up to Day 84 or end of Monotherapy Phase); Number of Participants With Worst-case Maximum Grade 2-4 Increase in Post-baseline Values of Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) Compared to the Baseline Values - Monotherapy Phase (Baseline (Day 1) and up to Day 84 or end of Monotherapy Phase); Number of Participants With Treatment-emergent Abnormal Electrocardiogram (ECG) Findings - Monotherapy Phase (Up to Day 84 or end of Monotherapy Phase); Number of Participants With Grade 2-4 Injection Site Reactions (ISR) - Monotherapy Phase (Up to Day 84 or end of Monotherapy Phase): Maximum Decline From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) Levels - Monotherapy Phase (Baseline (Day 1) and up to Day 84 or end of Monotherapy Phase): Part 1:GSK3810109A 40milligram(mg)/Kilogram Intravenously (IV) — Baseline (Day 1): 12258.5 Copies per milliliter (copies/mL) (range 1351 to 173710); Maximum decline from baseline (up to Day 84/end of Monotherapy Phase): -12014.5 Copies per milliliter (copies/mL) (range -171577 to -1312) | Part 1: GSK3810109A 280 mg IV — Baseline (Day 1): 30833 Copies per milliliter (copies/mL) (range 5938 to 104585); Maximum decline from baseline (up to Day 84/end of Monotherapy Phase): -26826.5 Copies per milliliter (copies/mL) (range -103583 to -5899) | Part 2: GSK3810109A 700 mg IV — Baseline (Day 1): 25466 Copies per milliliter (copies/mL) (range 7180 to 110387); Maximum decline from baseline (up to Day 84/end of Monotherapy Phase): -25966 Copies per milliliter (copies/mL) (range -107218 to -6944) | Part 2: GSK3810109A 70 mg IV — Baseline (Day 1): 25689.5 Copies per milliliter (copies/mL) (range 7225 to 683576); Maximum decline from baseline (up to Day 84/end of Monotherapy Phase): -14720.5 Copies per milliliter (copies/mL) (range -197793 to -4382) | Part 2: GSK3810109A 700 mg Subcutaneously (SC) — Baseline (Day 1): 23146 Copies per milliliter (copies/mL) (range 131 to 181078); Maximum decline from baseline (up to Day 84/end of Monotherapy Phase): -12584 Copies per milliliter (copies/mL) (range -178423 to -69) (not_applicable)

Result source: NCT04871113

Results for HIV

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.

Key endpoint3BNC117Lotivibart
HIV-1 RNA below 50 copies/mL (week 48)—Not reported—Not reported
HIV-1 RNA 50 copies/mL or more (week 48)—Not reported—Not reported
CD4 count, change (week 48)—Not reported—Not reported

HIV-1 RNA below 50 copies/mL (week 48)

3BNC117
—Not reported
Lotivibart
—Not reported

HIV-1 RNA 50 copies/mL or more (week 48)

3BNC117
—Not reported
Lotivibart
—Not reported

CD4 count, change (week 48)

3BNC117
—Not reported
Lotivibart
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. 3BNC117: 3 of 4 rows · Lotivibart: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metric3BNC117Lotivibart
Dropout rate
11.8%a
NCT02588586 · Phase 2 · registry result, not featured evidence · combination
show 2 more results
0%Group A: 3BNC117 IV + ART Interrup
NCT02446847 · Phase 2 · registry result, not featured evidence · combination
25%Group B: 3BNC117 IV + ART Interrup
NCT02446847 · Phase 2 · registry result, not featured evidence · combination
—700 mg IVb
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
show 12 more results
—700 mg SC
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
—700 mg IV
NCT04871113 · Phase 2 · combination · HIV · phase 2
—700 mg SC
NCT04871113 · Phase 2 · combination · HIV · phase 2
0%280 mg IV
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
—280 mg IV
NCT04871113 · Phase 2 · combination · HIV · phase 2
—70 mg IV
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
—70 mg IV
NCT04871113 · Phase 2 · combination · HIV · phase 2
0%40 mg/kg IV
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
—40 mg/kg IV
NCT04871113 · Phase 2 · combination · HIV · phase 2
12.5%3000 mg + rHuPH20
NCT05291520 · Phase 1 · combination
0%60 mg/kg
NCT05291520 · Phase 1 · monotherapy
0%20 mg/kg + rHuPH20
NCT05291520 · Phase 1 · combination
Discontinued due to AEs
—a
NCT02588586 · Phase 2 · registry result, not featured evidence · combination
show 2 more results
—Group A: 3BNC117 IV + ART Interrup
NCT02446847 · Phase 2 · registry result, not featured evidence · combination
—Group B: 3BNC117 IV + ART Interrup
NCT02446847 · Phase 2 · registry result, not featured evidence · combination
—700 mg IVb
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
show 12 more results
—700 mg SC
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
—700 mg IV
NCT04871113 · Phase 2 · combination · HIV · phase 2
—700 mg SC
NCT04871113 · Phase 2 · combination · HIV · phase 2
—280 mg IV
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
—280 mg IV
NCT04871113 · Phase 2 · combination · HIV · phase 2
—70 mg IV
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
—70 mg IV
NCT04871113 · Phase 2 · combination · HIV · phase 2
—40 mg/kg IV
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
—40 mg/kg IV
NCT04871113 · Phase 2 · combination · HIV · phase 2
—3000 mg + rHuPH20
NCT05291520 · Phase 1 · combination
—60 mg/kg
NCT05291520 · Phase 1 · monotherapy
—20 mg/kg + rHuPH20
NCT05291520 · Phase 1 · combination
Serious AEs
5.9%a
NCT02588586 · Phase 2 · registry result, not featured evidence · combination
show 2 more results
0%Group A: 3BNC117 IV + ART Interrup
NCT02446847 · Phase 2 · registry result, not featured evidence · combination
12.5%Group B: 3BNC117 IV + ART Interrup
NCT02446847 · Phase 2 · registry result, not featured evidence · combination
0%700 mg IVb
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
show 12 more results
0%700 mg SC
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
18.8%700 mg IV
NCT04871113 · Phase 2 · combination · HIV · phase 2
25%700 mg SC
NCT04871113 · Phase 2 · combination · HIV · phase 2
0%280 mg IV
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
0%280 mg IV
NCT04871113 · Phase 2 · combination · HIV · phase 2
0%70 mg IV
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
12.5%70 mg IV
NCT04871113 · Phase 2 · combination · HIV · phase 2
0%40 mg/kg IV
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
12.5%40 mg/kg IV
NCT04871113 · Phase 2 · combination · HIV · phase 2
0%3000 mg + rHuPH20
NCT05291520 · Phase 1 · combination
0%60 mg/kg
NCT05291520 · Phase 1 · monotherapy
0%20 mg/kg + rHuPH20
NCT05291520 · Phase 1 · combination
Most frequent reported AEs
a
malaise 23.5%
nausea 23.5%
diarrhea 17.6%
NCT02588586 · Phase 2 · registry result, not featured evidence · combination
show 2 more results
headache 75%
upper respiratory tract infection 62.5%
paresthesia upper extremity 37.5%
NCT02446847 · Phase 2 · registry result, not featured evidence · combination
upper respiratory tract infection 75%
headache 25%
anemia 12.5%
NCT02446847 · Phase 2 · registry result, not featured evidence · combination
700 mg IVb
influenza 12.5%
rhinitis 12.5%
aspartate aminotransferase increased 6.3%
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
show 12 more results
700 mg SC
headache 18.8%
blood creatine phosphokinase increased 12.5%
neutropenia 12.5%
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
700 mg IV
upper respiratory tract infection 18.8%
anaemia 12.5%
anogenital warts 6.3%
NCT04871113 · Phase 2 · combination · HIV · phase 2
700 mg SC
neutropenia 12.5%
pharyngitis 12.5%
tonsillitis 12.5%
NCT04871113 · Phase 2 · combination · HIV · phase 2
280 mg IV
abdominal pain 16.7%
asthenia 16.7%
bronchitis 16.7%
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
280 mg IV
depression 16.7%
hypertension 16.7%
influenza like illness 16.7%
NCT04871113 · Phase 2 · combination · HIV · phase 2
70 mg IV
covid-19 12.5%
alanine aminotransferase increased 6.3%
anal abscess 6.3%
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
70 mg IV
upper respiratory tract infection 12.5%
vomiting 12.5%
abdominal pain 6.3%
NCT04871113 · Phase 2 · combination · HIV · phase 2
40 mg/kg IV
abdominal pain 12.5%
blood creatine phosphokinase increased 12.5%
covid-19 12.5%
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
40 mg/kg IV
covid-19 25%
proctitis gonococcal 25%
syphilis 25%
NCT04871113 · Phase 2 · combination · HIV · phase 2
3000 mg + rHuPH20
injection site erythema 100%
injection site bruising 25%
injection site pain 25%
NCT05291520 · Phase 1 · combination
60 mg/kg
medical device site dermatitis 12.5%
muscle tightness 12.5%
covid-19 0%
NCT05291520 · Phase 1 · monotherapy
20 mg/kg + rHuPH20
injection site erythema 87.5%
upper respiratory tract infection 25%
headache 12.5%
NCT05291520 · Phase 1 · combination

Notes

  1. aPopulation comparability has not been reviewed for these studies.
  2. bPopulation comparability has not been reviewed for 3 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

3BNC117

Viral Rebound 86.7% (n=15) @ 36wk
event count · % of participants
No placebo or comparator arm
NCT02588586 · Phase 2 · registry result, not featured evidence · combination · converted to % from 13 Participants as posted
Time to Viral Rebound 1.27 months @ 36wk
time to event · months
No placebo or comparator arm
NCT02588586 · Phase 2 · registry result, not featured evidence · combination · converted to months from 5.5 weeks as posted
Virologic Rebound 66.7% (n=6) @ 8wk
event count · % of participants
No placebo or comparator arm
NCT02446847 · Phase 2 · registry result, not featured evidence · combination · converted to % from 4 Participants as posted
show 1 more result
37.5% (n=8) @ 8wk*
NCT02446847 · Phase 2 · registry result, not featured evidence · combination · converted to % from 3 Participants as posted

Lotivibart

HIV-1 RNA -25966 copies/mL @ 12wk700 mg IV
absolute change · copies/mL
No placebo or comparator arm
Maximum decline from baseline (up to Day 84/end of Monotherapy Phase)
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
show 4 more results
-12584 copies/mL @ 12wk700 mg SC
Maximum decline from baseline (up to Day 84/end of Monotherapy Phase)
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
-26826.5 copies/mL @ 12wk280 mg IV
Maximum decline from baseline (up to Day 84/end of Monotherapy Phase)
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
-14720.5 copies/mL @ 12wk70 mg IV
Maximum decline from baseline (up to Day 84/end of Monotherapy Phase)
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
-12014.5 copies/mL @ 12wk40 mg/kg IV
Maximum decline from baseline (up to Day 84/end of Monotherapy Phase)
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
CD4+ -3.3 cells/uL @ 12wk700 mg IV
absolute change · cells/uL
No placebo or comparator arm
CD4+, Day 84/end of Monotherapy Phase (compared with baseline)
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
show 4 more results
-19.6 cells/uL @ 12wk700 mg SC
CD4+, Day 84/end of Monotherapy Phase (compared with baseline)
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
30.2 cells/uL @ 12wk280 mg IV
CD4+, Day 84/end of Monotherapy Phase (compared with baseline)
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
-54.3 cells/uL @ 12wk70 mg IV
CD4+, Day 84/end of Monotherapy Phase (compared with baseline)
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
31.8 cells/uL @ 12wk40 mg/kg IV
CD4+, Day 84/end of Monotherapy Phase (compared with baseline)
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
CD4+ 134.9 cells/uL @ 48wk700 mg IV
absolute change · cells/uL
No placebo or comparator arm
CD4+, Week 48 of SOC Phase (compared with baseline)
NCT04871113 · Phase 2 · combination · HIV · phase 2
show 4 more results
247.3 cells/uL @ 48wk700 mg SC
CD4+, Week 48 of SOC Phase (compared with baseline)
NCT04871113 · Phase 2 · combination · HIV · phase 2
180.4 cells/uL @ 48wk280 mg IV
CD4+, Week 48 of SOC Phase (compared with baseline)
NCT04871113 · Phase 2 · combination · HIV · phase 2
233.8 cells/uL @ 48wk70 mg IV
CD4+, Week 48 of SOC Phase (compared with baseline)
NCT04871113 · Phase 2 · combination · HIV · phase 2
140 cells/uL @ 48wk40 mg/kg IV
CD4+, Week 48 of SOC Phase (compared with baseline)
NCT04871113 · Phase 2 · combination · HIV · phase 2

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: 3BNC117's landscape · Lotivibart's landscape